Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Multi-omics and experimental validation identify methylation-related genes and METTL16 as key regulators in diabetic foot ulcer pathogenesis

Tong Y., Li S., Shen L., Yan L., Zhu Z., Hua Q.

Laboratory Study on Diabetic Foot, Chronic Wound, Chronic Inflammation, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41310324
PMCID
PMC12661024
DOI
10.1038/s41598-025-26306-4
Citations
1

Abstract (original English)

Diabetic foot ulcers (DFUs) are a severe complication of diabetes, characterized by impaired wound healing, chronic inflammation, and tissue degradation. N 6 -methyladenosine (m 6 A), has emerged as a critical regulator in gene expression and cellular function in wound healing. This study aimed to systematically investigate the role of methylation-related genes (MRGs) in DFU pathogenesis, focusing on their diagnostic and therapeutic potential through integrative multi-omics analysis and experimental validation. Publicly available bulk RNA-seq, microarray, and single-cell RNA sequencing (scRNA-seq) datasets were analyzed to identify differentially expressed MRGs (DE-MRGs). Machine learning algorithms (LASSO, GBM, SVM-RFE, Random Forest) were used to screen key biomarkers. Immune infiltration and pathway enrichment analyses characterized inflammatory signatures, while scRNA-seq mapped MRG dynamics across cell types. Functional assays validated the role of METTL16 in high glucose-treated human skin fibroblasts (HSFs), assessing collagen synthesis, oxidative stress, and cellular migration. Thirteen DE-MRGs were identified in DFU tissues, with METTL16, NSUN3, and IGF2BP2 prioritized as diagnostic biomarkers. Immune profiling revealed M1 macrophage enrichment and dysregulated IL-17/MAPK pathways. Single-cell analysis highlighted METTL16's dynamic role in fibroblast activation and int

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
FibroblastsHumansDiabetic FootMethyltransferasesAdenosineGene Expression ProfilingWound HealingDNA MethylationGene Expression RegulationMethylation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research